European Journal of Cancer · 2022 · 40 citations · 16 references
MedicineDermatologyOncologyMetastasisMolecular OncologyTumor ProgressionCancer TranscriptomicsMelanocytic TumorsMolecular Tumor ProfilingStaging Of Skin CancerTranscriptomic ProfilingTumor ClassificationClinicopathologic FeaturesCutaneous Melanoma StagingMelanocytic Tumor Molecular PathologyMelanocytic Tumor PrognosisMelanoma BiomarkersMelanoma ClassificationMelanoma ProgressionTumor Profiling
PURPOSE: Patients with cutaneous melanoma stage I/IIA disease are currently not eligible for adjuvant therapy, despite their risk for relapses and death. This study validates the ability of a model combining clinicopathologic factors with gene expression profiling (CP-GEP) to identify patients at high risk for disease recurrence in stage I/II and subgroup stage I/IIA. PATIENTS AND METHODS: 543 patients with stage I/II primary cutaneous melanoma from the University of Tuebingen diagnosed between 2000 and 2017 were analysed. All patients received sentinel lymph node biopsy (SLNB). Analysis was conducted for a separate group of 80 patients who did not undergo SLNB. RESULTS: CP-GEP stratified 424 stage I/IIA patients (78% of the cohort) according to their risk for recurrence, with five-year relapse-free survival (RFS) rates of 77.8% and 93% for CP-GEP high risk (195 patients) and low risk (229 patients), respectively, and hazard ratio of 3.53 (p-value <0.001). In patients who did not receive SLNB biopsy, CP-GEP captured 6 out of 7 relapses. CONCLUSION: CP-GEP can be used to identify primary cutaneous melanoma patients with a high risk for disease recurrence - especially for stage I/IIA, who are considered low risk by AJCC 8th. These patients may benefit from adjuvant therapy. Also, in the future, when SLNB may become irrelevant, CP-GEP may serve as a risk stratification tool.
16
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 1.3K citations
Medicine, Oncology, Immunotherapy +15